Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients

Inclusion Criteria: Age Eligible for Study: 18 years - NA, Genders Eligible for Study: Both Criteria Inclusion criteria: * HIV infection * T CD4 count cell level above 200 per mm3 * Serology Hepatitis B negative (AgHBs, AbHBs and AbHBc negative) * unchanged ARV for the last 3 months for patients who are receiving ARV at the screening visit * Undetectable for the last 6 months with ARV for any patient with T CD4 level below 350 per mm3 * Pregnancy test negative at the screening and inclusion visits Exclusion Criteria: * Any injection of the vaccine against Hepatitis B in the medical history * Acute cytolysis in the last 3 months with transaminases equal or above 5 times the upper normal range for HIV-HCV coinfected patients, or transaminases equal or above 2 times the upper normal for non coinfected patients * Any vaccine received one month before the inclusion * History of intolerance to any component of GenHevac-B * Evolutive opportunistic infection treated the month before the screening visit * Severe and acute pyretic infection or unexplained fever the week before inclusion * Evolutive hemopathy or solid-organ cancer * Prothrombin factor equal or below 50 percent and/or platelets equal or below 50 000 per mm3 * Immunosuppressive treatment or general corticotherapy (equal or above 0,5 mg per kg per day during above 7 days) in the last 6 months before the screening visit * Previous Immunomodulating treatment (interferon, interleukin-2,etc) or plan in the next 6 months * Splenectomy * Decompensated cirrhosis (Child Pugh B or C) * Kidney deficient function (creatinine clearance below 50 ml per mn) * Other immunocompromised condition not related to HIV infection (solid-organ transplantation, chemotherapy in the last 6 months) * Any participation to another clinical trial plan until Week 28